The Company has more than 30 proprietary and partnered product candidates in development
Ablynx organises webcasts for analysts and investors on the occasion of financial results
Ablynx is listed on Euronext Brussels under the ticker symbol ABLX.
ABLYNX ANNOUNCES WARRANT EXERCISE
21 April 2015
FMR LLC PROVIDE NOTIFICATION OF SHAREHOLDING IN ABLYNX
15 April 2015
ABLYNX ANNOUNCES PUBLICATION OF 2014 ANNUAL REPORT AND LAUNCH OF NEW WEBSITE
07 April 2015
Ablynx’s proprietary Nanobody platform allows for the rapid generation and large-scale production of novel biological therapeutics that have potential in a wide range of human diseases.